Patricia Loranca-Moreno1, Juan Moises Ocampo-Godínez2, Alan Rios-Espinosa3, Magdalena Cruz-Luna3, Carolina Garmendia-Gallardo3, Merle Yasmin Hernández-Castañón3, Verónica Yazmin Hernández-Hernández3, Paula Mariana Sánchez-Tinoco3, Alma Bajonero-Domínguez3, Jael Adrián Vergara Lope-Núñez4,5, Marco Antonio Álvarez-Pérez4, José Luis González-Quiroz6. 1. Clínica de Peri-Postmenopausia Y Metabolismo Óseo, Instituto Politécnico Nacional, Hospital Regional 1° de Octubre ISSSTE. Av. 1669, 07760, Mexico City, Mexico. paty_lm_2502@hotmail.com. 2. Laboratorio de Bioingeniería de Tejidos, Departamento de Estudios de Posgrado E Investigación [DEPI] de La Facultad de Odontología, Universidad Nacional Autónoma de México [UNAM], 04510, Mexico City, Mexico. moisesoagj@gmail.com. 3. Clínica de Peri-Postmenopausia Y Metabolismo Óseo, Instituto Politécnico Nacional, Hospital Regional 1° de Octubre ISSSTE. Av. 1669, 07760, Mexico City, Mexico. 4. Laboratorio de Bioingeniería de Tejidos, Departamento de Estudios de Posgrado E Investigación [DEPI] de La Facultad de Odontología, Universidad Nacional Autónoma de México [UNAM], 04510, Mexico City, Mexico. 5. Central de Microscopía, Escuela Nacional de Ciencias Biológicas (ENCB), Instituto Politécnico Nacional (IPN), Prol. Carpio Y Plan de Ayala S/N, Col. Sto. Tomás, 11340, Mexico City, Mexico. 6. Laboratorio de Inmunoquímica I, Escuela Nacional de Ciencias Biológicas-IPN, 11340, Mexico City, Mexico.
Abstract
PURPOSE: This study aimed to determine the efficacy of non-hormonal therapy with citalopram vs fluoxetine for treating vasomotor syndrome (VMS) and urogenital syndrome of menopause (GSM) in Mexican women. METHODS: A parallel prospective randomized clinical trial was conducted in 91 postmenopausal women with a total score on the Menopause Rating Scale (MRS) ≥ 17 and with the clinical diagnosis of VSM and GSM. Patients were randomly assigned to receive citalopram (n = 49) or fluoxetine (n = 42). Follow-up was carried out at 3 and 6 months. RESULTS: The citalopram group experienced a significant improvement compared to the fluoxetine group in the MRS total score (p < 0.01), as well as in the psychological (p < 0.001) and somatic (p < 0.0001) domains at 3 and 6 months of follow-up. After 6 months of follow-up, the group that received citalopram decreased the relative risk (RR) to present VMS symptoms (RR = 0.30, CI 0.19-0.5, p = 0.0001), depressed mood (RR = 0.31, CI 0.15-0.6, p = 0.0002), irritability (RR = 0.40, CI 0.22-0.73, p = 0.002), anxiety (RR = 0.30, CI 0.13-0.69, p = 0.003), physical and mental exhaustion (RR = 0.35, CI 0.18-0.67, p = 0.001), sexual problems (RR = 0.18, CI 0.06-0.48, p = 0.0001), vaginal dryness (RR = 0.34, CI 0.14-0.80, p = 0.01), and urinary problems (RR = 0.36, CI 0.14-0.92, p = 0.043). CONCLUSION: We conclude that citalopram tends to improve VSM and GSM symptoms in postmenopausal Mexican women. Thus, we recommend the daily use of citalopram 20 mg. However, further studies will be required to support the results of the present work. These should include a larger number of patients and a placebo group. CLINICAL TRIAL REGISTRATION: This clinical trial was retrospectively registered by the United States National Library of Medicine in the www. CLINICALTRIALS: gov database on 04/20/2022. The given test Registration Number is NCT05346445.
PURPOSE: This study aimed to determine the efficacy of non-hormonal therapy with citalopram vs fluoxetine for treating vasomotor syndrome (VMS) and urogenital syndrome of menopause (GSM) in Mexican women. METHODS: A parallel prospective randomized clinical trial was conducted in 91 postmenopausal women with a total score on the Menopause Rating Scale (MRS) ≥ 17 and with the clinical diagnosis of VSM and GSM. Patients were randomly assigned to receive citalopram (n = 49) or fluoxetine (n = 42). Follow-up was carried out at 3 and 6 months. RESULTS: The citalopram group experienced a significant improvement compared to the fluoxetine group in the MRS total score (p < 0.01), as well as in the psychological (p < 0.001) and somatic (p < 0.0001) domains at 3 and 6 months of follow-up. After 6 months of follow-up, the group that received citalopram decreased the relative risk (RR) to present VMS symptoms (RR = 0.30, CI 0.19-0.5, p = 0.0001), depressed mood (RR = 0.31, CI 0.15-0.6, p = 0.0002), irritability (RR = 0.40, CI 0.22-0.73, p = 0.002), anxiety (RR = 0.30, CI 0.13-0.69, p = 0.003), physical and mental exhaustion (RR = 0.35, CI 0.18-0.67, p = 0.001), sexual problems (RR = 0.18, CI 0.06-0.48, p = 0.0001), vaginal dryness (RR = 0.34, CI 0.14-0.80, p = 0.01), and urinary problems (RR = 0.36, CI 0.14-0.92, p = 0.043). CONCLUSION: We conclude that citalopram tends to improve VSM and GSM symptoms in postmenopausal Mexican women. Thus, we recommend the daily use of citalopram 20 mg. However, further studies will be required to support the results of the present work. These should include a larger number of patients and a placebo group. CLINICAL TRIAL REGISTRATION: This clinical trial was retrospectively registered by the United States National Library of Medicine in the www. CLINICALTRIALS: gov database on 04/20/2022. The given test Registration Number is NCT05346445.
Authors: Olivia Raglan; Ilkka Kalliala; Georgios Markozannes; Sofia Cividini; Marc J Gunter; Jaya Nautiyal; Hani Gabra; Evangelos Paraskevaidis; Pierre Martin-Hirsch; Kostas K Tsilidis; Maria Kyrgiou Journal: Int J Cancer Date: 2019-02-20 Impact factor: 7.396
Authors: Philip Sarrel; David Portman; Patrick Lefebvre; Marie-Hélène Lafeuille; Amanda Melina Grittner; Jonathan Fortier; Jonathan Gravel; Mei Sheng Duh; Peter M Aupperle Journal: Menopause Date: 2015-03 Impact factor: 2.953